PL181867B1 - Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL - Google Patents

Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL

Info

Publication number
PL181867B1
PL181867B1 PL95317726A PL31772695A PL181867B1 PL 181867 B1 PL181867 B1 PL 181867B1 PL 95317726 A PL95317726 A PL 95317726A PL 31772695 A PL31772695 A PL 31772695A PL 181867 B1 PL181867 B1 PL 181867B1
Authority
PL
Poland
Prior art keywords
group
pyrrolidinyl
lower alkyl
formula
compound
Prior art date
Application number
PL95317726A
Other languages
English (en)
Polish (pl)
Other versions
PL317726A1 (en
Inventor
Kyoji Tomita
Katsumi Chiba
Shigeki Kashimoto
Koh-Ichiro Shibamori
Yasunori Tsuzuki
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of PL317726A1 publication Critical patent/PL317726A1/xx
Publication of PL181867B1 publication Critical patent/PL181867B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL95317726A 1994-06-14 1995-06-06 Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL PL181867B1 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13
PCT/JP1995/001110 WO1995034559A1 (en) 1994-06-14 1995-06-06 Novel compound, process for producing the same, and antitumor agent

Publications (2)

Publication Number Publication Date
PL317726A1 PL317726A1 (en) 1997-04-28
PL181867B1 true PL181867B1 (pl) 2001-09-28

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95317726A PL181867B1 (pl) 1994-06-14 1995-06-06 Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL

Country Status (27)

Country Link
US (1) US5817669A (OSRAM)
EP (1) EP0787726B1 (OSRAM)
JP (1) JP3391796B2 (OSRAM)
KR (1) KR100350921B1 (OSRAM)
CN (1) CN1053668C (OSRAM)
AT (1) ATE209645T1 (OSRAM)
AU (1) AU679859B2 (OSRAM)
BR (1) BR9508037A (OSRAM)
CA (1) CA2192824C (OSRAM)
CZ (1) CZ292631B6 (OSRAM)
DE (1) DE69524251T2 (OSRAM)
DK (1) DK0787726T3 (OSRAM)
ES (1) ES2163512T3 (OSRAM)
FI (1) FI112485B (OSRAM)
HK (1) HK1000495A1 (OSRAM)
HU (1) HU220072B (OSRAM)
MX (1) MX9606331A (OSRAM)
NO (1) NO307255B1 (OSRAM)
NZ (1) NZ287139A (OSRAM)
PL (1) PL181867B1 (OSRAM)
PT (1) PT787726E (OSRAM)
RO (1) RO117793B1 (OSRAM)
RU (1) RU2151770C1 (OSRAM)
SI (1) SI0787726T1 (OSRAM)
SK (1) SK281341B6 (OSRAM)
TW (1) TW319769B (OSRAM)
WO (1) WO1995034559A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212829A (pt) * 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
US7163948B2 (en) * 2003-04-07 2007-01-16 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine analogs
CN100410249C (zh) * 2003-09-10 2008-08-13 杏林制药株式会社 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
ES2358267T3 (es) * 2004-03-15 2011-05-09 Sunesis Pharmaceuticals, Inc. Composición farmacéutica que comprende sns-595 y sus usos.
KR100890533B1 (ko) * 2004-10-14 2009-03-27 에프. 호프만-라 로슈 아게 Ｃｄｋ1 저해제로서의 퀴나졸리닐메틸렌 티아졸리논
MX2007004276A (es) * 2004-10-14 2007-05-16 Hoffmann La Roche 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1.
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
US7563805B2 (en) 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
WO2007022474A2 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
AU2006287149B2 (en) * 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
CA2845095A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20080045279A (ko) * 2005-09-14 2008-05-22 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
EP2354138A1 (en) 2006-06-12 2011-08-10 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
SI2049109T1 (sl) * 2006-08-02 2016-04-29 Sunesis Pharmaceuticals, Inc. Kombinirana uporaba(+)-1,4-dihidro-7-((3s,4s)-3-metoksi-4-(metilamino)- 1-pirolidinil)-4-okso-1-(2-tiazolil)-1,8-naftiridin-3-karboksilne kisline in citarabina (ara-c) za zdravljenje levkemije
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
RU2548031C2 (ru) 2008-12-31 2015-04-10 Санесис Фармасьютикалз, Инк. Способ получения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты
NZ594829A (en) 2009-02-27 2013-09-27 Sunesis Pharmaceuticals Inc Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
SG10201913053QA (en) * 2011-05-13 2020-03-30 Array Biopharma Inc Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
AU2018238079B2 (en) 2017-03-24 2022-03-03 Wakunaga Pharmaceutical Co., Ltd. Novel pyridone carboxylic acid derivative or salt thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
NZ216519A (en) * 1985-06-13 1989-02-24 Schering Corp Polycyclic compounds and pharmaceutical compositions
WO1986007357A2 (en) * 1985-06-14 1986-12-18 Upjohn Co Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
FI112485B (fi) 2003-12-15
SK281341B6 (sk) 2001-02-12
EP0787726B1 (en) 2001-11-28
HUT75777A (en) 1997-05-28
NO965305D0 (no) 1996-12-11
CZ292631B6 (cs) 2003-11-12
RU2151770C1 (ru) 2000-06-27
AU679859B2 (en) 1997-07-10
PL317726A1 (en) 1997-04-28
JP3391796B2 (ja) 2003-03-31
EP0787726A4 (OSRAM) 1997-08-06
HU220072B (hu) 2001-10-28
FI965020A0 (fi) 1996-12-13
CZ364396A3 (en) 1997-06-11
FI965020A7 (fi) 1996-12-16
HK1000495A1 (en) 2002-07-19
CA2192824A1 (en) 1995-12-21
NO965305L (no) 1997-02-04
TW319769B (OSRAM) 1997-11-11
SI0787726T1 (en) 2002-04-30
NO307255B1 (no) 2000-03-06
CA2192824C (en) 2006-11-07
ATE209645T1 (de) 2001-12-15
KR100350921B1 (ko) 2002-11-18
BR9508037A (pt) 1997-09-16
HU9603455D0 (en) 1997-02-28
DK0787726T3 (da) 2002-02-11
SK157496A3 (en) 1997-08-06
RO117793B1 (ro) 2002-07-30
MX9606331A (es) 1997-03-29
US5817669A (en) 1998-10-06
CN1053668C (zh) 2000-06-21
CN1158614A (zh) 1997-09-03
NZ287139A (en) 1997-07-27
EP0787726A1 (en) 1997-08-06
PT787726E (pt) 2002-04-29
WO1995034559A1 (en) 1995-12-21
AU2576795A (en) 1996-01-05
ES2163512T3 (es) 2002-02-01
DE69524251D1 (de) 2002-01-10
DE69524251T2 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
PL181867B1 (pl) Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL
JPWO1995034559A1 (ja) 新規化合物、その製法および抗腫瘍剤
HK1000495B (en) Novel compound, process for producing the same, and antitumor agent
KR102894761B1 (ko) 치환된 헤테로환형 융합된 환형 화합물, 이의 제조 방법 및 이의 약학적 용도
EP2044077B1 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
JP4323574B2 (ja) 抗腫瘍剤
KR101946911B1 (ko) 신규한 인돌리진 유도체, 이의 제조 방법 및 이를 함유하는 약제 조성물
IE903801A1 (en) Camptothecin analogs as potent inhibitors of human¹colorectal cancer
JPH06116269A (ja) トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
JP2015519387A (ja) Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
CZ299794B6 (cs) Analogy kamptothecinu, zpusob jejich prípravy a farmaceutické prostredky obsahující tyto analogy
JP2818198B2 (ja) Ｎ‐（５，６，７，８‐テトラヒドロピリド［２，３‐ｄ］ピリミジン‐６‐イルアルカノイル）グルタミン酸誘導体
JPH06211852A (ja) 新規なエリプチシン化合物、それら化合物の製造法及びそれら化合物を含有する製剤組成物
TWI422589B (zh) 化合物
KR20010051779A (ko) 캄프토세신 유사 화합물, 이들의 제조 방법, 및 이들을함유하는 약제 조성물
JP5079612B2 (ja) 抗腫瘍剤
WO2023155826A1 (zh) 一类多取代三环并杂环化合物及其药用组合物和应用
CN108948003B (zh) 作为mTOR抑制剂的吡嗪并[2,3-c]喹啉-2（1H）-酮类化合物的制备及用途
HU192728B (en) Process for producing 4-oxo-pyrido/2,3-d/pyrimidine derivatives and pharmaceutical compositions containing them
JPH0873460A (ja) １，８−ナフチリジン化合物および抗腫瘍剤
EP1458720B1 (en) 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
WO1997031919A1 (en) Pyridonecarboxylic acid derivatives and intermediates for the synthesis thereof
CN116635076A (zh) 大环化合物及其用途
WO1994014813A1 (en) Novel quinolone derivatives and processes for preparing the same
JP2002114785A (ja) １，８−ナフチリジン誘導体および抗腫瘍剤